Rituximab Dosing for Nephrotic Syndrome in Children

Dosing Calculation

The recommended dose of rituximab for a child with nephrotic syndrome is 375 mg/m² per dose, with 1-4 doses typically administered depending on clinical response and CD20 levels, as recommended by the Kidney International guidelines 1, 2, 3
To calculate the dose, first determine the child's body surface area (BSA) using standard formulas, such as the Mosteller formula, then multiply by 375 mg/m² 1, 3
For a typical 25kg child, the BSA is approximately 0.95-1.0 m², resulting in a dose of approximately 356-375 mg per infusion 3

Rituximab should be administered as an intravenous infusion, according to the Kidney International guidelines 1, 2
CD20 levels should be monitored to guide treatment duration and response, as recommended by the Kidney International guidelines 1
The number of doses (1-4) depends on clinical response and institutional protocols, as stated in the Kidney International guidelines 1, 3

Prior to rituximab administration, check hepatitis B surface antigen, hepatitis B core antibody, and QuantiFERON test for tuberculosis, as recommended by the Kidney International guidelines 1, 2
IgG levels should be monitored both before and after rituximab therapy to identify risk for developing significant infection, according to the Kidney International guidelines 1
Ensure the child has achieved remission with glucocorticoids before initiating rituximab, as recommended by the Kidney International guidelines 4

Rituximab is indicated for steroid-sensitive nephrotic syndrome in children who have continuing frequent relapses despite optimal combinations of prednisone and glucocorticoid-sparing oral agents, as stated in the Kidney International guidelines 1, 2
It is also indicated when children experience serious adverse effects from standard therapy, according to the American Journal of Kidney Diseases guidelines 1, 5
Rituximab is typically used as an alternative agent rather than first-line therapy, as recommended by the Kidney International guidelines 1, 2

Consider immunoglobulin replacement in patients with persistently low IgG levels after treatment, as recommended by the Kidney International guidelines 1
Monitor for infusion reactions during administration, although this is based on a guideline from Praxis Medical Insights, an alternative source is preferred, however, this is the only available information 6